In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...

City of Hope® Research Spotlight offers a glimpse at groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells.

Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say researchers from the University of Leeds and The Institute of Cancer Research.

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

Frontline therapy for multiple myeloma has intensified over the years ... it would be feasible and possible to leukapherese and manufacture CAR T cells in this post-transplant setting when patients ...

Paris was hospitalized for an immediate blood transfusion and eventual stem cell transplant. “Paris began experiencing weakness, particularly in his spine… almost breaking his back.” Films like Strong ...

The off-the-shelf chimeric antigen receptor (CAR) T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor activity in patients with relapsed/refractory multiple myeloma ... had ...

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

Please provide your email address to receive an email when new articles are posted on . Taking beta blockers may raise mortality risk for HSCT recipients due to suppression of signals from nerves ...

Multiple myeloma is currently not curable, but we can manage the disease effectively for years. For active myeloma, treatment may include chemotherapy, proteasome inhibitors, immune-modifying drugs or ...